Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Current Leases (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Current Leases for 10 consecutive years, with $441000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases changed N/A year-over-year to $441000.0, compared with a TTM value of $441000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $420000.0, down 22.65% over the prior year.
  • Current Leases was $441000.0 for Q3 2025 at Zevra Therapeutics, down from $589000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $596000.0 in Q2 2024 and bottomed at $336000.0 in Q1 2021.
  • Average Current Leases over 5 years is $445133.3, with a median of $456000.0 recorded in 2023.
  • The sharpest move saw Current Leases skyrocketed 37.13% in 2022, then dropped 22.65% in 2024.
  • Year by year, Current Leases stood at $356000.0 in 2021, then skyrocketed by 34.83% to $480000.0 in 2022, then increased by 13.12% to $543000.0 in 2023, then dropped by 22.65% to $420000.0 in 2024, then rose by 5.0% to $441000.0 in 2025.
  • Business Quant data shows Current Leases for ZVRA at $441000.0 in Q3 2025, $589000.0 in Q1 2025, and $420000.0 in Q4 2024.